{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"259"},{"groupId":"OG001","value":"394"}],"units":"Participants"}],"description":"The decimal values of percentages were subjected to rounding off.","groups":[{"description":"Ixazomib citrate placebo-matching capsules, orally, once on Days 1, 8 and 15 in a 28-day cycle for Cycles 1 through 26 until progressive disease (PD), unacceptable toxicity, or discontinuation for alternate reasons.","id":"OG000","title":"Placebo"},{"description":"Ixazomib citrate 3 mg, capsules, orally, once, on Days 1, 8 and 15 in a 28-day cycle for Cycles 1 through 4. Ixazomib citrate 4 mg, capsules, orally, once, on Days 1, 8 and 15 in a 28-day cycle for Cycles 5 through 26 until PD, unacceptable toxicity, or discontinuation for alternate reasons. Participants who had any dose reductions due to AEs were not dose escalated.","id":"OG001","title":"Ixazomib Citrate"}],"paramType":"NUMBER","populationDescription":"Safety Population was defined as participants who received at least 1 dose of ixzaomib citrate or placebo.","reportingStatus":"POSTED","timeFrame":"Up to 107 months","title":"Percentage of Participants Who Develop a New Primary Malignancy","type":"SECONDARY","unitOfMeasure":"percentage of participants"}